Novel MAS receptor activator shows potential for SMA

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Oct 12 / Springer Healthcare

Novel MAS receptor activator shows potential for SMA

Neuroscience Spinal Muscular Atrophy WMS-2022

Description

Cynthia Bézier discusses findings from a preclinical study showing that BIO101 – a novel orally administered compound that activates the MAS receptor – may represent a promising treatment option for spinal muscular atrophy.

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.